Abstract
Magnetic resonance imaging (MRI) contrast agents have an important role to differentiate healthy and diseased tissues. Access and design new contrast agents for the optimal use of MRI are necessary. This study aims to evaluate iron oxide-4A nanocomposite ability to act as a magnetic resonance imaging contrast agent. Iron oxide-4A nanocomposite (F4A) was synthesized. MTT assay was used to consider the nanocomposite safety for cell culture. The T1 and T2 relaxation times were measured using a 1.5 Tesla clinical MRI scanner. Then the corresponding relaxivities were determined. The average particle diameter of the nanocomposite was 50 to 100 nm based on scanning electron microscope (SEM) image. A linear relationship between relaxation rates and the Fe concentration of the nanocomposite was obtained. The T1 and T2 relaxivities of the nanocomposite were calculated 5.413 and 1092.1 mM-1.s-1, respectively which led to the T2/T1 relaxivity ratio of 201.75. The high T2/T1 relaxivity ratio of the iron oxide-4A nanocomposite confirms it's potential to act as a T2 contrast agent.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
